FACS

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Retrieved on: 
Tuesday, March 19, 2024
Retina, University of Nevada, Reno, Houston Methodist Hospital, Webcast, Associate, ASX, KOL, University, Doctor of Philosophy, MBA, University of Illinois Urbana-Champaign, Shore, AMD, FACS, Medicine, Pharmaceutical industry

Additionally, Opthea will provide a strategic outlook.

Key Points: 
  • Additionally, Opthea will provide a strategic outlook.
  • A live question and answer session will follow the formal presentations.
  • To register for this live webcast, click here .
  • A replay of the webcast will be made available on the Company’s website.

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

Retrieved on: 
Monday, March 18, 2024
Harvard Medical School, Worldwide, Research, Doctor of Philosophy, Protein, Regius Professor, Skin, Secretome, Safety, FACS, FRCS, BLA, Peptide, Vaccine

Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.

Key Points: 
  • Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.
  • Carmell’s technology was previously being developed as a BLA and has Phase 2 human clinical data supporting safety and efficacy.
  • In comparison, other aesthetic products feature 1-2 synthetic proteins with sparse evidence of clinical efficacy.
  • Carmell aims to launch a limited-edition product this month followed by 9 other skincare products over the summer 2024.

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Retrieved on: 
Tuesday, March 12, 2024
Deep vein thrombosis, Pulmonary embolism, VTE, Incidence, Sequela, CAVA, Patient, Post-thrombotic syndrome, Research, PTS, DVT, Randomized controlled trial, Safety, FACS, American Venous Forum, Data, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.

Key Points: 
  • IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
  • The interim results are the largest prospective, multi-center two-year dataset in deep vein thrombosis (DVT) since the ATTRACT trial and confirm the excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in real-world DVT patients.
  • Patients had low incidence of independently adjudicated safety events related to rethrombosis, with only 5.0% and 8.4% at 30-days and 6 months, respectively.
  • We remain committed to establishing the ClotTriever and FlowTriever systems as standard of care for deep vein thrombosis and pulmonary embolism (PE) patients.”

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Tuesday, April 2, 2024
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Shift, Principal, CPI, Drainage, Environment, Refractive surgery, ASCRS, Patient, COE, Acquisition, Faculty, Cataract, MBA, CPC, Society, Safety, Paradigm shift, Pharma, FACS, CPMA, FDA, Annual general meeting, Pharmaceutical industry

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.

Key Points: 
  • Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024.
  • LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
  • “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma, Inc., has increased our internal know-how and assets.
  • This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Practice Management, Optical, Surgery, General Health, Health, Hospitals, Other Health, Presbyopia, ASCRS, Patient, Social media, Near-sightedness, Lens, Cataract, Astigmatism, EVO, STAAR, Surgeon, Publication, Society, Booth, FACS, Multimedia, Behavior, FDA, Reflexive relation, Communications satellite

Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.

Key Points: 
  • Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.
  • STAAR Surgical can be found at Booth 527 and additional ASCRS event information is available at https://ascrs.org/annual-meeting .
  • View the full release here: https://www.businesswire.com/news/home/20240402599401/en/
    “EVO ICL is the next logical step in refractive innovation.
  • The website offers surgeons access to a wealth of resources, including publications, key clinical outcomes data, and more.

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Tuesday, March 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Interventional radiology, Thrombosis, TLR9, MDSC, Immunotherapy, Drug, Progression-free survival, Patient, Cancer, Bleeding, Society, University, Neoplasm, MD Anderson Cancer Center, Pancreas, FACS, Liver

Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.

Key Points: 
  • Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.
  • In PERIO-03, nelitolimod is delivered via the PEDD method with the TriSalus Infusion System using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • There were no immediate complications from the procedure, and there was no evidence of hemorrhage or thrombosis.
  • Local tumor progression-free survival rates across organs at one month, six months, and one year were 94%, 80%, and 70%, respectively.

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Interventional radiology, Pressure, Immunotherapy, Drug, Safety, Partnership, Patient, Pancreas, Tumor microenvironment, Society of Interventional Radiology, Metastasis, Publication, Pancreatic cancer, Therapy, FACS, FDA, Liver, SIR, Food, Medical imaging

The TriSalus approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors.

Key Points: 
  • The TriSalus approach seeks to address many of the key challenges associated with delivering therapeutics to pancreas tumors.
  • In contrast to the liver, pancreas arteries feeding tumors are difficult to access and venous access affords anatomic advantages.
  • Presentation details for SIR 2024 are as follows:
    Presentation: Clinical Efficacy of Pressure-Enabled Transarterial Embolization of Hypovascular, Treatment-Refractory Metastases.
  • Location: Salt Lake Palace Convention Center, Room 255B
    The presentations will be available on the publications page of the TriSalus website following the respective sessions.

Blessings in a Backpack, Jim & Tabitha Furyk Foundation and Nemours Children’s Health Raise Awareness of Childhood Food Insecurity at THE PLAYERS Championship

Retrieved on: 
Friday, March 15, 2024
Golf, General Sports, Family, Consumer, Other Education, Other Philanthropy, Philanthropy, Sports, Primary, Secondary, Parenting, Education, Children, Fund Raising, Foundation, Clay, Organization, Jim, LOVE, Hunger, Environment, Partnership, Food, Smith, Food security, MD, Student, FAAP, FACS, The Players Championship, Toy

On Wednesday, March 12, the Jim & Tabitha Furyk Foundation and Nemours Children’s Health joined Blessings in a Backpack at THE PLAYERS Championship Kid Zone for the second consecutive year to address childhood hunger in the community.

Key Points: 
  • On Wednesday, March 12, the Jim & Tabitha Furyk Foundation and Nemours Children’s Health joined Blessings in a Backpack at THE PLAYERS Championship Kid Zone for the second consecutive year to address childhood hunger in the community.
  • View the full release here: https://www.businesswire.com/news/home/20240315917128/en/
    On Wednesday, March 12, the Jim & Tabitha Furyk Foundation and Nemours Children’s Health joined Blessings in a Backpack at THE PLAYERS Championship Kid Zone for the second consecutive year to address childhood hunger in the community.
  • The organizations packed bags of food for Blessings in a Backpack recipients.
  • Students also had the opportunity to collect autographs from their favorite golfers at the Autograph Zone, presented by Nemours Children’s Health.

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) IS NOW ACCEPTING APPLICATIONS FOR TWO AACS CERTIFIED COSMETIC SURGERY FELLOWSHIP TRAINING PROGRAMS

Retrieved on: 
Monday, April 1, 2024
AACS, Interest, DDS, Patient, Breast, American Academy, Surgeon, Plastic surgery, Rhinoplasty, Skin, Blepharoplasty, Extremities, FACS, DMD, Physician, Dentistry

CHICAGO, April 1, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty organization for physicians dedicated to cosmetic surgery and aesthetic medicine, is accepting applications for July 2025 cohort positions for two types of AACS Certified Fellowship Training Programs. Applications are due by June 1, 2024.

Key Points: 
  • Applications for AACS Certified Cosmetic Surgery Fellowships in General Cosmetic Surgery and Facial Cosmetic Surgery, which offer comprehensive, world-class training, will be accepted until June 1, 2024 for July 2025 cohort positions
    CHICAGO, April 1, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS) , the world's largest multi-specialty organization for physicians dedicated to cosmetic surgery and aesthetic medicine, is accepting applications for July 2025 cohort positions for two types of AACS Certified Fellowship Training Programs.
  • AACS Certified Cosmetic Surgery Fellowships are the only cosmetic surgery training programs that fully prepare physicians for a career in cosmetic surgery, offering extraordinary opportunities for intensive, hands-on training in a vast array of cosmetic surgery procedures alongside some of the world's leading cosmetic surgeons.
  • Offered in General Cosmetic Surgery and Facial Cosmetic Surgery, these Certified Fellowships are post‐residency programs involving advanced education and comprehensive training in the art of general cosmetic surgery and facial cosmetic surgery.
  • Ryan Diepenbrock, DDS, FAACS, Chair of the Facial Cosmetic Surgery Fellowship Committee, adds, "AACS Fellowships provide the training needed to successfully practice as a cosmetic surgeon.